Pro32Pro33 mutations in the integrin β3 PSI domain result in αIIbβ3 priming and enhanced adhesion: reversal of the hypercoagulability phenotype by the Src inhibitor SKI-606.
The plasma-membrane integrin αIIbβ3 (CD41/CD61, GPIIbIIIa) is a major functional receptor in platelets during clotting. A common isoform of integrin β3, Leu33Pro is associated with enhanced platelet function and increased risk for coronary thrombosis and stroke, although these findings remain controversial. To better understand the molecular mechanisms by which this sequence variation modifies platelet function, we produced transgenic knockin mice expressing a Pro32Pro33 integrin β3. Consistent with reports utilizing human platelets, we found significantly reduced bleeding and clotting times, as well as increased in vivo thrombosis, in Pro32Pro33 homozygous mice. These alterations paralleled increases in platelet attachment and spreading onto fibrinogen resulting from enhanced integrin αIIbβ3 function. Activation with protease-activated receptor 4- activating peptide, the main thrombin signaling receptor in mice, showed no significant difference in activation of Pro32Pro33 mice as compared with controls, suggesting that inside-out signaling remains intact. However, under unstimulated conditions, the Pro32Pro33 mutation led to elevated Src phosphorylation, facilitated by increased talin interactions with the β3 cytoplasmic domain, indicating that the αIIbβ3 intracellular domains are primed for activation while the ligand-binding domain remains unchanged. Acute dosing of animals with a Src inhibitor was sufficient to rescue the clotting phenotype in knockin mice to wild-type levels. Together, our data establish that the Pro32Pro33 structural alteration modifies the function of integrin αIIbβ3, priming the integrin for outside-in signaling, ultimately leading to hypercoagulability. Furthermore, our data may support a novel approach to antiplatelet therapy by Src inhibition where hemostasis is maintained while reducing risk for cardiovascular disease.
Departments of Pharmacology (K.H.O., T.J., C.Y.C., A.M.C.) and Psychiatry, Molecular Physiology, and Biophysics (E.L.C., J.S.S.), Vanderbilt University Medical Center, Nashville, Tennessee.
Kendra H
KH
Oliver
Tammy
T
Jessen
Emily L
EL
Crawford
Chang Y
CY
Chung
James S
JS
Sutcliffe
Ana M
AM
Carneiro
D000595:Amino Acid Sequence; D000814:Aniline Compounds / Q000494:pharmacology*; D000818:Animals; D001483:Base Sequence; D002448:Cell Adhesion / Q000235:genetics*; D017931:DNA Primers; D006801:Humans; D039661:Integrin beta3 / Q000737:chemistry / Q000235:genetics*; D051379:Mice; D008969:Molecular Sequence Data; D009154:Mutation; D009570:Nitriles / Q000494:pharmacology*; D010641:Phenotype; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000235:genetics / Q000502:physiology*; D016133:Polymerase Chain Reaction; D011392:Proline / Q000235:genetics*; D011804:Quinolines / Q000494:pharmacology*; D017386:Sequence Homology, Amino Acid; D019851:Thrombophilia / Q000235:genetics*; D019061:src-Family Kinases / Q000037:antagonists & inhibitors*
D000814:Aniline Compounds; D017931:DNA Primers; D039661:Integrin beta3; D009570:Nitriles; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011804:Quinolines; C471992:bosutinib; D011392:Proline; D019061:src-Family Kinases